PT141//sales05@ycphar.com

PT141//sales05@ycphar.com

PT141//sales05@ycphar.com

CAS No.:32780-32-8、189691-06-3
Bremelanotide (formerly PT-141) is a drug which is or has been under development by Palatin Technologies as a treatment for female sexual dysfunction (FSD), hemorrhagic shock, and reperfusion injury. Bremelanotide was originally tested for intranasal administration in treating FSD but this application was temporarily discontinued in 2008 after concerns were raised over adverse side effects of increased blood pressure. As of December 2014, Palatin is conducting a human phase III study[2] using a subcutaneous drug delivery system that appears to have little effect on blood pressure.

Skype:sales05_267
Email: sales05@ycphar.com
Tel:86-027-50756082
whatsApp:+8618872220733
PT141//sales05@ycphar.com

CAS No.:32780-32-8、189691-06-3
Bremelanotide (formerly PT-141) is a drug which is or has been under development by Palatin Technologies as a treatment for female sexual dysfunction (FSD), hemorrhagic shock, and reperfusion injury. Bremelanotide was originally tested for intranasal administration in treating FSD but this application was temporarily discontinued in 2008 after concerns were raised over adverse side effects of increased blood pressure. As of December 2014, Palatin is conducting a human phase III study[2] using a subcutaneous drug delivery system that appears to have little effect on blood pressure.

Skype:sales05_267
Email: sales05@ycphar.com
Tel:86-027-50756082
whatsApp:+8618872220733